BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Bipolar disorder clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for bipolar disorder: 35 (24 sponsors; 2 newly posted in the last 180 days, 2 stopped in the last 180 days; 2 new-entrant sponsors). Momentum score 15.7, rank 40 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 0, Phase 1 3, Phase 2 9, Phase 3 11, Phase 4 2, N/A 10.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Bristol-Myers Squibb BMY4P3 400
Alkermes, Inc. ALKS2P3 200
Intra-Cellular Therapies, Inc.2P3 200
Xenon Pharmaceuticals Inc. XENE2P3 200
AbbVie ABBV4P2 2, P1 1, P3 103
Neurocrine Biosciences NBIX2P2 1, P4 100
Psyrin Inc.2NA 200
Akrivia Health1NA 100
Alcediag1NA 100
Alto Neuroscience ANRO1P2 100
Alzamend Neuro, Inc. ALZN1P2 100
Autobahn Therapeutics, Inc.1P2 100
BioXcel Therapeutics Inc BTAIQ1P1 100
Boryung Pharmaceutical Co., Ltd1NA 100
Bosnalijek D.D new entrant1NA 111
diaMentis Inc.1NA 101
Eli Lilly and Company LLY1P2 100
Gaize1NA 100
LB Pharmaceuticals Inc. LBRX1P2 100
Mapi Pharma Ltd.1P2 101
Neurelis, Inc. new entrant1P1 111
Vanda Pharmaceuticals VNDA1P4 100
Vielight Inc.1NA 100
Zimmer Biomet ZBH1NA 101

New-entrant sponsors: Bosnalijek D.D, Neurelis, Inc..

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12-31 est.P1/P2Mapi Pharma Ltd.NCT07185815 Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for TreatmenSchizophrenia; Bipolar I Disorder; Major Depressive Disorderrecruiting24

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-02 est.P3Bristol-Myers Squibb BMYNCT06951711 A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)Bipolar Disorder Type I With Mania or Mania With Mixed Featuresrecruiting274
2026-11-01 est.P3Bristol-Myers Squibb BMYNCT06951698 A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I DisorderBipolar-I Disorder With Mania or Mania With Mixed Featuresrecruiting274
2026-09 est.P3Alkermes, Inc. ALKSNCT05303064 Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I DisorderSchizophrenia; Bipolar I Disorderrecruiting220
2026-08-05P2Rapport Therapeutics Inc. RAPPNCT07046494 Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I DisorderBipolar 1 Disordercompleted253

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "bipolar disorder"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.